PRESS RELEASES More events are coming soon. Keyword Search Year: 202120202019201820172016201520142013 01/06/21 Summary ToggleTRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Printer Friendly PDF Version 12/30/20 Summary ToggleTRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab Oncology and 3D Medicines Printer Friendly PDF Version 12/29/20 Summary ToggleTRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering Printer Friendly PDF Version 12/22/20 Summary ToggleTRACON Pharmaceuticals Announces $8.8 Million Registered Direct Offering Printer Friendly PDF Version 12/10/20 Summary ToggleTRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal Trial Printer Friendly PDF Version 11/23/20 Summary ToggleTRACON Announces Publication in Cancer Cell of Clinical Data that Provides Molecular Insight into the Mechanism of Action of TRC102 and Patient Populations Most Likely to Respond to Treatment Printer Friendly PDF Version 11/16/20 Summary ToggleTRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D Medicines Printer Friendly PDF Version 11/10/20 Summary ToggleTRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update Printer Friendly PDF Version 11/03/20 Summary ToggleTRACON to Report Third Quarter 2020 Financial Results and Company Highlights on November 10, 2020 Printer Friendly PDF Version 10/26/20 Summary ToggleTRACON Announces FDA Orphan Drug Designation for TRC102 in Malignant Glioma, Including Glioblastoma Printer Friendly PDF Version Pagination First page First Previous page Previous … Page 2 Current page 3 Page 4 Page 5 … Next page Next Last page Last
